Rituximab (Rituximab) effects and efficacy

Rituximab (Rituximab) is an anti-tumor drug. Rituximab is used as a monotherapy for relapsed or refractory low-grade or follicular antigenCD20positiveB cell non-Hodgkin lymphoma (NHL). Treatment of previously untreated follicular, antigenCD20positiveBcellsNHL in combination with chemotherapy. As monotherapy for the treatment of non-progressive (e.g., stable disease), low-grade, antigenCD20positiveB cellNHL after first-line treatment with CVPchemotherapy. Treatment of previously untreated diffuse large Bcell antigenCD20positive non-Hodgkin lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or other anthracycline-based chemotherapy. Rituximab is indicated in combination with fludarabine and cyclophosphamide (FC) for the treatment of previously untreated and previously treated antigenCD20positive chronic lymphocytic leukemia (CLL). Rituximab is used in combination with methotrexate for treatment of patients with ≥1tumor necrosis factor (TNFTNF-α) blockers. The manufacturer states that use is not recommended in patients with an inadequate response to ≥1 TNF blocker. Rituximab for idiopathic thrombocytopenic purpura in adults. Rituximab is used in combination with immunoglobulin IV to treat refractory pemphigus vulgaris.

Rituximab monotherapy is highly effective in several types of indolent lymphoma, with response rates (RRs) ranging from 45% to 60%< even in pretreated patients /span>, while in the more aggressive NHL types, RRs are about 30%. Rituximab is a chimeric monoclonal antibody directed against CD20, a surface antigen found on B cells. Thus, it acts by depleting normal and pathogenic B cells, while sparing plasma cells and hematopoietic stem cells, since they do not express the CD20 surface antigen. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.